The Avandia debate: an unhappy conclusion

J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / prevention & control
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetic Cardiomyopathies / chemically induced
  • Diabetic Cardiomyopathies / drug therapy
  • Diabetic Cardiomyopathies / prevention & control
  • Europe
  • Government Agencies
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Myocardial Infarction / chemically induced*
  • Randomized Controlled Trials as Topic
  • Rosiglitazone
  • Thiazolidinediones / adverse effects*
  • Thiazolidinediones / therapeutic use
  • United States
  • United States Food and Drug Administration

Substances

  • Hypoglycemic Agents
  • Insulin
  • Thiazolidinediones
  • Rosiglitazone